Novo Nordisk

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Novo Nordisk A/S
Type Publicly traded Aktieselskab
Traded as OMXNOVO B
NYSENVO
Industry Pharmaceuticals, health care
Founded 1923
Headquarters Bagsværd, Denmark
Key people Sten Scheibye (Chairman), Lars Rebien Sørensen (President and CEO), Jesper Brandgaard (CFO)
Products Activella, Novolin,
Levemir, NovoSeven, Norditropin, Tresiba
Revenue DKK 78.02 billion (2012)[1]
Operating income DKK 29.47 billion (2012)[1]
Profit DKK 21.43 billion (2012)[1]
Total assets DKK 65.66 billion (2012)[1]
Total equity DKK 40.63 billion (2012)[1]
Employees 35,154 (2012)[1]
Website www.novonordisk.com

Novo Nordisk manufactures and markets pharmaceutical products and services and was created in 1989 through a merger of two Danish companies dating back to the 1920s. It produces, in particular, diabetes care equipment and medications. Novo Nordisk is also involved with haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies [2]

Company headquarters are in Denmark, with production facilities in seven countries, and affiliates or offices in 76 countries. It employed approximately 38,483 people globally as of Q4 2013, and marketed its products in 179 countries. It is the largest publicly traded company in the Nordic countries by market capitalization.[3]

Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[4]

The company was ranked 25th among 100 best companies to work for in 2010 by Fortune.[5] In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights.[citation needed]

The company makes several drugs under various brand names. Some of them are Levemir, NovoLog, Novolin R, NovoSeven, and Victoza. The Novo Nordisk logo since the year after the company’s foundation has been the Apis bull, one of the sacred animals of ancient Egypt.

Collaborative research[edit]

Toxicogenomics[edit]

Novo Nordisk is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[6][7] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[8]

Diabetes[edit]

Novo Nordisk founded the World Diabetes foundation[9] to save the lives of those affected by diabetes in developing countries and supported a UN resolution to fight diabetes, making diabetes the only other disease alongside HIV / AIDS to have a commitment to combat at a UN level.

Unite for Diabetes[edit]

Novo Nordisk have sponsored the International Diabetes Federation's Unite for Diabetes campaign.[10]

Controversies[edit]

In 2010 Novo Nordisk breached the ABPIs code of conduct by failing to provide information about side-effects of Victoza and by promoting Victoza prior to being granted market authorization.[11]

In 2013 Novo Nordisk had to pay back DKK 3.6 billion to the Danish tax authorities due to transfer mispricing.[12]

See also[edit]

References[edit]

  1. ^ a b c d e f "Annual Report 2010". Novo Nordisk. Retrieved 6 February 2011. 
  2. ^ "Biopharmaceutical Research Unit," Novo Nordisk Corporation, accessed November 29, 2011, http://www.novonordisk.com/science/organisation/bru.asp
  3. ^ Boyd, Jonathan. "Pharma replaces oil as biggest Nordic market cap maker". Investment Europe. Retrieved 4 April 2012. 
  4. ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Retrieved 2008-08-25. 
  5. ^ Money.CNN.com
  6. ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.  edit
  7. ^ "InnoMed PredTox Member Organizations". Retrieved 2008-08-25. 
  8. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25. [dead link]
  9. ^ "World Diabetes Foundation website". Retrieved 2008-08-25. 
  10. ^ Wordldiabetesday.org
  11. ^ "Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd and Napp Pharmaceuticals Limited named in advertisements". Prescription Medicines Code of Practice Authority (PMCPA). Retrieved 2011-02-07. 
  12. ^ "Sådan snød Novo Nordisk Skat for 3,6 milliarder". Retrieved 2013-02-05. 

External links[edit]